December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Combination therapy with CPI-0610, a novel BET inhibitor, plus ruxolitinib shows promising activity in JAK inhibitor–naive patients with myelofibrosis in this phase II study.